Postapproval Cardio Studies Challenged By Enrollment, Protocol Issues
This article was originally published in The Gray Sheet
FDA’s assessments of strengths and weaknesses for eight years’ worth of completed cardiovascular trials show about one-third of studies are challenged by enrollment, protocol or bias issues, according to a graphical analysis by "The Gray Sheet."
You may also be interested in...
Our most popular stories last month included an exclusive item on FDA's next steps for its device Case-for-Quality program; a graphical analysis of the agency's MDUFA III performance, three years into the program; a guest column from a former CDRH Office of Compliance director; and more.
A planning board created to develop a framework for a new U.S. medical device surveillance system has proposed a seven year plan on how to get the system up and running, which will include creating incentive systems for stakeholders as well as reducing the burden of recording and managing device data.
Small sample sizes and delays in reaching protocol agreements are hindering FDA’s ability to use postapproval study data to track device performance, says a study in JAMA Internal Medicine.